Adults with high‑ or very high‑risk acute leukemia (AL) and myelodysplastic syndrome (MDS) face substantial risk of disease relapse after allogeneic hematopoietic stem‑cell transplantation. Cord blood (CB) is an alternative stem‑cell source with a potent graft‑versus‑leukemia effect but historically limited by low cell dose and delayed engraftment. UM171 is a small molecule used for ex vivo expansion of CB units to increase progenitor cell numbers prior to infusion. The combined results of two prospective phase II trials assessed whether a single‑unit UM171‑expanded CB transplant is feasible and provides timely engraftment, acceptable non‑relapse mortality, durable disease control, and manageable graft‑versus‑host disease (GVHD) in a high‑risk adult population.
Two single‑arm, prospective phase II trials conducted at four centers enrolled 64 adults with high‑ or very high‑risk AL or MDS. Of those, 60 patients received a UM171‑expanded CB transplant and comprised the analysis population. The cohort was enriched for adverse features: 32% had a prior transplant, 17% of patients with AL were not in remission at the time of transplantation, and among patients with AML/MDS, 24% harbored TP53 mutations. These characteristics reflect a population at elevated risk for relapse and transplant failure.
CB units were preferentially selected at a 5/8 HLA match to prioritize graft‑versus‑leukemia activity while allowing for UM171‑mediated expansion to address low cell dose constraints. Of 62 patients who remained eligible for transplantation, a graft was successfully manufactured and infused for 60 patients, demonstrating high feasibility of the ex vivo expansion and manufacturing workflow for single‑unit UM171‑expanded CB grafts.
Patients received intermediate‑ or high‑intensity conditioning regimens as appropriate for disease risk and comorbidity. Graft‑versus‑host disease prophylaxis consisted of tacrolimus combined with mycophenolate mofetil. The source document reports these prophylactic strategies but does not provide further regimen‑specific details beyond the agents and intensity categories.
Primary and secondary endpoints included measures of safety and feasibility, hematopoietic recovery (neutrophil and platelet engraftment times), non‑relapse mortality (NRM), cumulative incidence of relapse, overall survival (OS), relapse‑free survival (RFS), acute and chronic GVHD, GVHD‑free relapse‑free survival (GRFS), and chronic GVHD‑free relapse‑free survival (CRFS). The trials report time‑to‑event outcomes and cumulative incidence estimates at prespecified landmark intervals.
Manufacturing and infusion were successful for nearly all eligible patients: 60 of 62 eligible patients received a graft. Median time to neutrophil engraftment was 17 days and median time to platelet engraftment was 38 days. These intervals indicate relatively prompt hematopoietic recovery compared with historical CB experience without expansion, supporting the potential of UM171 expansion to accelerate engraftment after single‑unit CB transplantation.
Early transplant mortality was limited: NRM was 5.1% at day 100 and 15.2% at 1 year. The two‑year cumulative incidence of relapse was 22.3%. At two years, overall survival was 63.9% and relapse‑free survival was 60.4%. These outcomes were obtained in a population that included previously transplanted patients, those transplanted with active disease, and patients with adverse molecular features, indicating disease control durable enough to warrant further evaluation.
Clinically significant acute and chronic GVHD rates were reported. Grade III–IV acute GVHD incidence was 20.3% at 1 year. Moderate‑to‑severe chronic GVHD incidence was 6.8% at 2 years, a relatively low frequency of debilitating chronic GVHD in this cohort. GRFS and CRFS were prespecified endpoints in the trials, but detailed numeric values for those composite endpoints beyond those reported in the primary summary were not provided in the source abstract.
Competing interests and industry relationships are disclosed in the source. Several investigators have financial ties to ExCellThera, which holds the license for UM171; these include consulting fees, clinical trial funding, equity, and entitlement to royalties for some authors. Ethical approvals were obtained from relevant institutional review boards and oversight bodies for each participating center, and all participants provided written informed consent. The source notes that the article is a preprint and has not undergone peer review.
Combined results from the two phase II trials indicate that single‑unit UM171‑expanded cord blood transplantation is feasible in adults with high‑ and very high‑risk AL and MDS, with prompt neutrophil and platelet engraftment, acceptable NRM, durable disease control at two years, and infrequent clinically significant chronic GVHD. Given the single‑arm design and the preprint status of the report, the authors conclude that comparative studies versus contemporary donor platforms are warranted to define the role of UM171‑expanded CB transplantation in current practice.
The trials are registered (NCT03913026 and NCT04103879). The authors state that all data produced in the study are available upon reasonable request. The document is a preprint and has not been peer reviewed; the source cautions that the findings should not yet be used to guide clinical practice.